Pfizer
PFE NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$29.79
KIRA · Stoqly’s AI analyst, in plain words
- Pfizer had $62.6B of revenue in fiscal 2025, down 1.7% on the year before. Over five years, revenue changed +8.5% a year on average.
- Pfizer made $7.8B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 1.7% a year.
- Free cash flow was $9.1B in fiscal 2025, 14.5% of revenue.
- Pfizer returned $9.8B to shareholders in fiscal 2025, 108% of free cash flow. The diluted share count rose 0.2%.
- Pfizer owes $54.3B more than it holds in cash, about 3.2 years of operating profit.
Market cap
$169.8B
P/E
39.2x
Revenue
$62.6B
Net income
$7.8B
Free cash flow
$9.1B
Operating margin
—
Pfizer in 30 seconds · fiscal 2025
Are sales growing?
−1.7%
No. Sales fell 1.7% last year.
Does it make a profit?
12.4%
Yes. It keeps 12.4% of every sale as profit.
Does profit turn into cash?
14.5%
Yes. 14.5% of sales ends up as free cash.
Is debt under control?
3.2x
Heavy. Repaying its debt would take 3.2 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
39.2x
One share costs 39.2 times its yearly profit per share. Typical for its sector: 27.9x.
What Pfizer does
Pfizer discovers, develops, makes and sells prescription medicines and vaccines, and supplies them to about 200 countries and territories. Its products include Eliquis, part of its internal medicine portfolio, vaccines such as the Prevnar family, Comirnaty and Abrysvo, the COVID-19 treatment Paxlovid, and cancer drugs such as Ibrance, Xtandi and Padcev. It sells its medicines mainly to wholesalers, and also directly to retailers, hospitals, clinics, pharmacies and government agencies. Most of Pfizer's revenue comes from making and selling these products, and Biopharma is its only reportable segment. It also runs PC1, which develops and manufactures drugs for other companies under contract. In 2025, 12 products each brought in more than $1 billion, together 65% of total revenue; Eliquis alone was 13%. Revenue from outside the U.S. was $25.5 billion, or 41% of the total.
Biggest risks, in its own words
- Losing sales when patents and exclusivity rights expire and cheaper generic drugs or biosimilars reach the market.
- Its reliance on a small group of large products, such as Eliquis, and on a few large customers for much of its revenue.
- Pressure on drug prices from governments, insurers and benefit managers, including its voluntary deal with the U.S. government to lower prices.
- Acquisitions and other deals, such as its purchase of Metsera, may not bring the benefits it expects.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- PFIZER INC
- CIK
- 0000078003
Pfizer · PFE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Revenue growth | 95.2% | 24.5% | −41.1% | 6.8% | −1.7% |
| Gross margin | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Net margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Cash | |||||
| Cash from operations | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B |
| Capital expenditure | $2.7B | $3.2B | $3.9B | $2.9B | $2.6B |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| FCF margin | 36.7% | 25.7% | 8.1% | 15.5% | 14.5% |
| Dividends paid | $8.7B | $9.0B | $9.2B | $9.5B | $9.8B |
| Share buybacks | $0.0M | $2.0B | $0.0M | $0.0M | $0.0M |
| Share count change | 1.4% | 0.4% | −0.4% | −0.2% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $24.0B | $19.2B | $7.3B | $11.9B | $10.3B |
| Debt incl. finance leases | $37.8B | $35.4B | $71.8B | $63.6B | $64.6B |
| Shareholders' equity | $77.2B | $95.7B | $89.0B | $88.2B | $86.5B |
| Net debt / EBITDA | 0.5x | 0.4x | 6.8x | 2.9x | 3.2x |
| Current ratio | 1.4x | 1.2x | 0.9x | 1.2x | 1.2x |
| Interest coverage | 19.8x | 29.1x | 1.5x | 3.6x | 3.8x |
| Returns and quality | |||||
| Return on capital | 32.0% | 32.0% | 2.5% | 7.6% | 7.3% |
| Return on equity | 31.3% | 36.3% | 2.3% | 9.1% | 8.9% |
| Piotroski F-score | 6 | 6 | 4 | 8 | 6 |
| Altman Z'' | 4.2 | 4.6 | 2.4 | 3.1 | 3.1 |
Insiders bought, 12 months
$3.0M
3 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pfizer · PFE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Pfizer PFE | $169.8B | −1.7% | — | 14.5% | 7.3% | 39.2x | 6 |
| Johnson & Johnson JNJ | $652.1B | 6.1% | — | 20.9% | 28.6% | 40.4x | 4 |
| AbbVie ABBV | $507.8B | 8.6% | 24.7% | 29.1% | 15.7% | 81.0x | 7 |
| Moderna MRNA | $79.1B | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $29.79 a share, the company is worth $169.8B: 39.2 times its earnings of the last four quarters.
Pfizer grew sales faster than 1 of its 3 similar companies. Its P/E is higher than 0 of 2.
Source: SEC EDGAR XBRL filings (CIK 0000078003). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.